ArticleFrontiers in oncology2025
Trajectories of perioperative serum CEA and non-small cell lung cancer prognosis: a retrospective longitudinal cohort study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Value of serum CEA and CA19-9 dynamic changes and trajectory modeling in prognosis assessment for non-small cell lung cancer.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of postoperative carcinoembryonic antigen (CEA) levels in non-small lung cancer (NSCLC) prognostic evaluation remains unclear. Additionally, the dynamic changes in CEA levels during the perioperative period have not been fully characterized. Methods: We retrospectively reviewed stage I-IIIA NSCLC patients who underwent curative resection. A latent class growth mixed model was employed to categorize patients into distinct CEA trajectory groups. The Kaplan-Meier method assessed the relationship between CEA trajectory groups and recurrence-free survival (RFS) and overall survival (OS). Multivariate analysis of perioperative CEA levels in relation to RFS and overall survival OS was performed using Cox proportional hazards regression. Results: A total of 5733 patients were included in our study. Elevated postoperative CEA levels were associated with higher risks of recurrence (HR = 2.64, 95% CI: 1.65-4.23) and mortality (HR = 3.34, 95% CI: 2.09-5.80) compared to normal CEA levels. Furthermore, patients with normal preoperative CEA but elevated postoperative levels also had higher risks of recurrence (HR = 3.00, 95% CI: 1.77-5.10) and mortality (HR = 3.30, 95% CI: 1.79-6.07). Three CEA trajectory categories were identified: low-stable, early-rising, and later-rising. Compared to the low-stable group, the early-rising group had significantly higher risks of recurrence (HR = 10.84, 95% CI: 5.57-21.10) and mortality (HR = 13.37, 95% CI: 5.45-32.81). The later-rising group had lower, but still significant, risks of recurrence (HR = 3.56, 95% CI: 1.62-7.81). Conclusion: Continuous postoperative monitoring of CEA levels in NSCLC patients is essential, especially for those with elevated postoperative CEA levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.